Company Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies.
Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia.
The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.
Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023.
The company was incorporated in 2019 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2019 |
| IPO Date | Sep 13, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 114 |
| CEO | Leon Moulder |
Contact Details
Address: North Building, Suite 1200 Waltham, Massachusetts 02451 United States | |
| Phone | 857 271 2954 |
| Website | zenasbio.com |
Stock Details
| Ticker Symbol | ZBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001953926 |
| ISIN Number | US98937L1052 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Leon Oliver Moulder Jr., M.B.A. | Chief Executive Officer and Chairman of the Board |
| Joseph L. Farmer | Chief Operating Officer and President |
| Jennifer A. Fox | Chief Business Officer and Chief Financial Officer |
| Dr. Tanya Z. Fischer M.D., Ph.D. | Head of Research and Development and Chief Medical Officer. |
| Jeffrey Held | Chief Legal Officer |
| Caroline Chevalier | Chief Human Resources Officer |
| Orlando Oliveira | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 2, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 23, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 16, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |